Design, synthesis, cytocidal activity and estrogen receptor α affinity of doxorubicin conjugates at 16α-position of estrogen for site-specific treatment of estrogen receptor positive breast cancer

Steroids

Volumn 77, Issue 11, 2012, Pages 1113-1122

  Saha, Pijus ^a   Fortin, Sébastien ^a   Leblanc, Valérie ^a   Parent, Sophie ^a   Asselin, Éric ^a   Bérubé, Gervais ^a  

^a UNIVERSITÉ DU QUÉBEC À TROIS RIVIÈRES   (Canada)

Author keywords

Biological activity; Breast cancer; Doxorubicin; Estradiol conjugate; Estrogen; Estrogen receptor alpha

Indexed keywords

16BETA HYDROXYMETHYL 1,3,5(10) ESTRATRIEN 3,17 DIOL 16AALPH OCTANOIC ACID N DOXORUBICINAMIDE; 16BETA HYDROXYMETHYL 1,3,5(10) ESTRATRIEN 3,17 DIOL 16ALPHA DECANOIC ACID N DOXORUBICINAMIDE; 16BETA HYDROXYMETHYL 1,3,5(10) ESTRATRIEN 3,17 DIOL 16ALPHA HEXANOIC ACID N DOXORUBICINAMIDE; 3 TETRAHYDROPYRANNYLOXY 1,3,5(10) ESTRATRIEN 17 ONE; AMIDE; ANTINEOPLASTIC AGENT; CARBON; DOXORUBICIN DERIVATIVE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; HYDROXYL GROUP; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL LINE; CELL STRAIN MCF 7; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; NONHUMAN; RECEPTOR BINDING;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; NEOPLASMS, HORMONE-DEPENDENT; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84865514941     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2012.06.004     Document Type: Article

References (41)

1. American Cancer Society, Cancer facts & figures 2011, Atlanta: American Cancer Society, 2011.
2. W.F. Anderson, H.A. Katki, and P.S. Rosenberg Incidence of breast cancer in the United States: current and future trends J Natl Cancer Inst 103 2011 1397 1402
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin D. GLOBOCAN 2008 v12, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No 10, Lyon, France: International Agency for Research on Cancer, 2010 Available from: < http://globocaniarcfr >, [accessed on 14th, March 2012].
4. World Health organiztion, Fact sheet on cancer no 297, Globocan 2008, IARC, February 2011, Available from: http://www.who.int/mediacentre/factsheets/ fs297/en/, [accessed on 14th, March 2012].
5. R.B. Weiss The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 19 1992 670 686
6. H.G. Keizer, H.M. Pinedo, G.J. Schuurhuis, and H. Joenje Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity Pharmacol Ther 47 1990 219 231
7. K. Dhingra, D. Frye, R.A. Newman, R. Walters, R. Theriault, and G. Fraschini Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer Clin Cancer Res 1 1995 691 697
8. B.A. Johnson, M.S. Cheang, and G.J. Goldenberg Comparison of adriamycin uptake in chick embryo heart and liver cells an murine L5178Y lymphoblasts in vitro: role of drug uptake in cardiotoxicity Cancer Res 46 1986 218 223
9. T.J. Lampidis, L.V. Johnson, and M. Israel Effects of adriamycin on rat heart cells in culture: increased accumulation and nucleoli fragmentation in cardiac muscle v. non-muscle cells J Mol Cell Cardiol 13 1981 913 924
10. K.M. Kasiotis, P. Magiatis, H. Pratsinis, A. Skaltsounis, V. Abadji, and A. Charalambous Synthesis and biological evaluation of novel daunorubicin-estrogen conjugates Steroids 66 2001 785 791
11. S.A. Khan, M.A. Rogers, K.K. Khurana, M.M. Meguid, and P.J. Numann Estrogen receptor expression in benign breast epithelium and breast cancer risk J Natl Cancer Inst 90 1998 37 42
12. G. Soderqvist Effects of sex steroids on proliferation in normal mammary tissue Ann Med 30 1998 511 524
13. M. Lesniewska, W. Miltyk, J. Swiatecka, M. Tomaszewska, M. Kuzmicki, and J. Palka Estrogen receptor β participate in the regulation of metabolizm of extracellular matrix in estrogen α negative breast cancer Folia Histochem Cytobiol 47 2009 S107 S112
14. J. Quivy, G. Leclercq, M. Deblaton, P. Henrot, N. Velings, and B. Norberg Synthesis, structure and biological properties of Z-17α-(2-iodovinyl)- 11β-chloromethyl estradiol-17β (Z-CMIV), a high affinity ligand for the characterization of estrogen receptor-positive tumors J Steroid Biochem Mol Biol 59 1996 103 117
15. R. Devraj, J.F. Barrett, J.A. Fernandez, J.A. Katzenellenbogen, and M. Cushman Design, synthesis, and biological evaluation of ellipticine-estradiol conjugates J Med Chem 39 1996 3367 3374
16. M. Georgiadis, K.P. Chondros, and S.A. Haroutounian Synthesis and biological studies of steroidal cis-platinum (II) complexes Inorg Chim Acta 138 1987 249 252
17. J.P. DiZio, K.E. Carlson, C.J. Bannochie, M.J. Welch, E. Von Angerer, and J.A. Katzenellenbogen Estrogen platinum-diamine complexes: preparation of a non-steroidal estrogen platinum-diamine complex labeled with platinum-191 and a study of its binding to the estrogen receptor in vitro and its tissue distribution in vivo J Steroid Biochem Mol Biol 42 1992 363 373
18. G.M. Anstead, K.E. Carlson, and J.A. Katzenellenbogen The estradiol pharmacophore: ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site Steroids 62 1997 268 303
19. H.S. Aliabadi, and J.E. Brown Synthesis, analysis and biological evaluation of novel steroidal estrogenic prodrugs for the treatment of breast cancer Pharmaceut Biol 42 2004 367 373
20. Hartman NG, Angelucci F, Suarato A. United Kingdom Patent GB 2201419 A (Application Number 8704236); 1988.
21. N.G. Hartman, L.H. Patterson, P. Workman, A. Suarato, and F. Angelucci Doxorubicin-3'-NH-oestrone-17-oxime-ethyl-carbonyl, a doxorubicin-oestrone conjugate that does not redox cycle in rat liver microsomes Biochem Pharmacol 40 1990 1164 1167
22. C. Descôteaux, V. Leblanc, G. Belanger, S. Parent, É. Asselin, and G. Bérubé Improved synthesis of unique estradiol-linked platinum(II) complexes showing potent cytocidal activity and affinity for the estrogen receptor α and β Steroids 73 2008 1077 1089
23. C. Descôteaux, J. Provencher-Mandeville, I. Mathieu, V. Perron, S.K. Mandal, and É. Asselin Synthesis of 17β-estradiol platinum(II) complexes: biological evaluation on breast cancer cell lines Bioorg Med Chem Lett 13 2003 3927 3931
24. J. Provencher-Mandeville, C. Debnath, S.K. Mandal, V. Leblanc, S. Parent, and É. Asselin Design, synthesis and biological evaluation of estradiol-PEG-linked platinum(II) hybrid molecules: comparative molecular modeling study of three distinct families of hybrids Steroids 76 2011 94 103
25. J. Provencher-Mandeville, C. Descôteaux, S.K. Mandal, V. Leblanc, É. Asselin, and G. Bérubé Synthesis of 17β-estradiol- platinum(II) hybrid molecules showing cytotoxic activity on breast cancer cell lines Bioorg Med Chem Lett 18 2008 2282 2287
26. C. Van Themsche, S. Parent, V. Leblanc, C. Descôteaux, A.M. Simard, and G. Bérubé VP-128, a novel oestradiol-platinum(II) hybrid with selective anti-tumour activity towards hormone-dependent breast cancer cells in vivo Endocr Relat Cancer 16 2009 1185 1195
27. D.D. Perrin, and W.L.F. Armarego Purification of laboratory chemicals 3rd ed. 1988 Pergamon Press Oxford
28. W.C. Still, M. Kahn, and A. Mitra Rapid chromatographic techniques for preparative separation with moderate resolution J Org Chem 43 1978 2923 2925
29. R.J. Petroski Improved preparation of halopropyl bridged carboxylic ortho esters Org Commun 1 2008 48 53
30. S.J. Zhang, Q.F. Ge, D.W. Guo, W.X. Hu, and H.Z. Liu Synthesis and anticancer evaluation of α-lipoic acid derivatives Bioorg Med Chem Lett 20 2010 3078 3083
31. Harwood LM, Moody CJ. Experimental Organic Chemistry- Principles and Practice (Functional group interconversion, pp 440-538, Chapter 07) Blackwell Scientific Publications: Oxford, London; 1989.
32. National Cancer Institute (NCI/NIH), Developmental therapeutics program human tumor cell line screen. Available from: http://dtp.nci.nih.gov/branches/ btb/ivclsp.html [accessed on 14th, March 2012].
33. R.M. Eglen Enzyme fragment complementation: a flexible high throughput screening assay technology Assay drug dev technol 1 2002 97 104
34. E. Baral, and G. Auer In vitro effect of doxorubicin on non-proliferating and proliferating epithelial cells Int J Radiat Oncol Biol Phys 19 1990 963 965
35. Perron V, Rabouin D, Asselin É, Parent S, C.-Gaudreault R, Bérubé, G. Synthesis of 17β-estradiol-linked platinum(II) complexes and their cytocidal activity on estrogen-dependent and -independent breast tumor cells. Bioorg Chem 2005;33:1-15.
36. C.N. N'Soukpoe-Kossi, C. Descôteaux, É. Asselin, H.A. Tajmir-Riahi, and G. Bérubé DNA interaction with novel antitumor estradiol-platinum(II) hybrid molecule: a comparative study with cisplatin drug DNA Cell Biol 27 2008 101 107
37. C.N. N'Soukpoe-Kossi, C. Descôteaux, É. Asselin, and J. Bariyanga A, Bérubé G. Transfer RNA bindings to antitumor estradiol-platinum(II) hybrid and cisplatin DNA Cell Biol 27 2008 337 343
38. P. Saha, C. Descôteaux, K. Brasseur, S. Fortin, V. Leblanc, and S. Parent Synthesis, antiproliferative activity and estrogen receptor α affinity of novel estradiol-linked platinum(II) complex analogs to carboplatin and oxaliplatin Potential vector complexes to target estrogen-dependent tissues Eur J Med Chem 48 2012 385 390
39. E. Froehlich, A. Gupta, J. Provencher-Mandeville, É. Asselin, J. Bariyanga, and G. Bérubé Study of DNA interactions with steroidal and nonsteroidal estrogen-platinum (ii)-based anticancer drugs DNA Cell Biol 28 2009 31 39
40. A. Lau, G. Bérubé, C.H.J. Ford, and M. Gallant Novel doxorubicin anti-carcinoembryonic antigen antibody immunoconjugate activity in vitro Bioorg Med Chem 3 1995 1305 1312
41. C.C. Wong, K.W. Cheng, and B. Rigas Preclinical predictors of anticancer drug efficacy: critical assessment with emphasis on whether nanomolar potency should be required of candidate agents J Pharmacol Exp Ther 341 2012 572 578